Debiopharm Highlights Clinical Momentum Across DDR Portfolio at ESMO 2026, Advancing WEE1-Based Therapies in Ovarian and Uterine Cancers and Glioblastoma

Contributed by: Business Wire

Logo

Tags

Research

Clinical Trials

Other Health

Biotechnology

General Health

Pharmaceutical

Health

Science

Oncology

Other Science

Debiopharm

More Like This

Debiopharm Launches Expansion of WEE1 Inhibitor Monotherapy Research in Gynecological Cancers and Other Biomarker-driven Solid Tumors

Debiopharm to Unveil New Pre-Clinical and Clinical Research Advances in DDR Inhibition, Dual Payload ADCs, and AI-Driven Biomarkers at AACR 2026

Debiopharm Ignites Oncology Innovation With Clinical and Translational Data on Debio 0123 at the 2025 ASCO Annual Meeting in Chicago

Debiopharm to Showcase Research Results of Their DDR Inhibitors at the 2024 AACR Conference in San Diego

Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer

Debiopharm to Reveal Insights From Their ADC, DDR Inhibitor, and Antibody Conjugation Technology Research at the 2025 AACR Conference in Chicago

Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition

Debiopharm and Repare Therapeutics Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer